Ben
Lehman

IP Strategist

Seattle, Washington, US

I love travelling to the Northern hemisphere. When the days in Australia are starting to get longer and the nights colder, the other side of the world is just starting to emerge from the cold. It's a great contrast (and good fun packing a t-shirt in the middle of winter).

photo credit: B Mully

Browse Scorecards

All Scorecards RSS

This Scorecard RSS

Click here to receive Global IP Scorecards™ by email

Gleevec / Glivec (Imatinib)

Contribute to this scorecard

Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It was originally coded during development as CGP57148B or STI-571 (these terms are used in early preclinical publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

Updates by Country

(Click on a country name to view)

(sort countries by most recently updated)

All | India | Thailand | United States